Spinocerebellar ataxia: patient and health professional perspectives on whether and how patents affect access to clinical genetic testing.
Genetic testing for spinocerebellar ataxia is used in diagnosis of rare movement disorders. Such testing generally does not affect treatment, but confirmation of mutations in a known gene can confirm diagnosis and end an often years-long quest for the cause of distressing and disabling symptoms. Through interviews and a web forum hosted by the National Ataxia Foundation, patients and health professionals related their experiences with the effect of patents on access to genetic testing for spinocerebellar ataxia. In the United States, Athena Diagnostics holds either a patent or an exclusive license to a patent in the case of six spinocerebellar ataxia variants (spinocerebellar ataxia 1-3 and 6-8) and two other hereditary ataxias (Friedreich's Ataxia and Early Onset Ataxia). Athena has enforced its exclusive rights to spinocerebellar ataxia-related patents by sending notification letters to multiple laboratories offering genetic testing for inherited neurological conditions, including spinocerebellar ataxia. Roughly half of web forum respondents had decided not to get genetic tests. Price, coverage and reimbursement by insurers and health plans, and fear of genetic discrimination were the main reasons cited for deciding not to get tested. Price was cited as an access concern by the physicians, and as sole US provider, coverage and reimbursement depend on having payment agreements between Athena and payers. In cases in which payers do not reimburse, the patient is responsible for payment, although some patients can apply to the voluntary Athena Access and Patient Protection Plan offered by the company.
Powell
Ashton
A
Center for Public Genomics, Center for Genome Ethics, Law and Policy, Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA.
Chandrasekharan
Subhashini
S
Cook-Deegan
Robert
R
D004180:Direct Service Costs; D006282:Health Personnel; D006297:Health Services Accessibility / Q000191:economics*; D006801:Humans; D019458:Insurance Coverage; D008004:Licensure; D010330:Patents as Topic; D010361:Patients / Q000523:psychology; D011287:Prejudice; D020754:Spinocerebellar Ataxias / Q000175:diagnosis* / Q000235:genetics
Neurology. 2006 Jun 13;66(11):1717-20
16769946
Dev Med Child Neurol. 2000 Apr;42(4):283-6
10795570
Nat Rev Neurosci. 2004 Aug;5(8):641-55
15263894
Arch Neurol. 2000 Apr;57(4):540-4
10768629
Arch Neurol. 2003 Jun;60(6):858-63
12810491
Mov Disord. 2005 Nov;20(11):1405-12
16037936
Am J Med Genet. 1997 May 31;74(3):270-4
9184309
Clin Chem. 2007 Jun;53(6):1016-22
17446330
Eur J Neurol. 2005 Nov;12(11):851-7
16241973
Ann Neurol. 1997 Dec;42(6):933-50
9403487
Neurology. 2002 Mar 12;58(5):702-8
11889231
Brain. 1982 Mar;105(Pt 1):1-28
7066668
Neuro Endocrinol Lett. 2005 Apr;26(2):98-108
15855879
Lancet Neurol. 2004 May;3(5):291-304
15099544
Neuroepidemiology. 2001 May;20(2):144-9
11359084
Arch Neurol. 2004 Jun;61(6):875-80
15210524
Brain. 2003 Mar;126(Pt 3):685-91
12566288
Am J Hum Genet. 1990 Jun;46(6):1163-77
1971152
J Mol Diagn. 2003 Feb;5(1):3-8
12552073
Cerebellum. 2005;4(1):2-6
15895552
Ann Neurol. 1998 Mar;43(3):288-96
9506544
Cerebellum. 2005;4(1):62-73
15895563
Nature. 1999 Nov 11;402(6758):118
10646997
Medicine (Baltimore). 1970 May;49(3):227-41
4910986
Neurology. 1998 Dec;51(6):1666-71
9855520